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Abstract Otitis media is the second most common infection in children and the leading cause for seeking medical advice. Indigenous populations such as the Inuits, indigenous Australians and American Indians have a very high prevalence of otitis media and are considered to be high-risk populations. Streptococcus pneumoniae, one of the three main bacterial causes of otitis media, colonises the nasopharynx prior to disease development. In high-risk populations, early acquisition of high bacterial loads increases the prevalence of otitis media. In these settings, current treatment strategies are insufficient. Vaccination is effective against invasive pneumococcal infection but has a limited impact on otitis media. Decreasing the bacterial loads of otitis media pathogens and/or colonising the nasopharynx with beneficial bacteria may reduce the prevalence of otitis media. Probiotics are live microorganisms that offer health benefits by modulating the microbial community and enhancing host immunity. The available data suggest that probiotics may be beneficial in otitis media. This review discusses the potential use of probiotics to reduce pathogen colonisation and decrease the prevalence of otitis media, providing justification for further investigation.
Otitis media
Otitis media (OM) is the second most common childhood infection [1] [2] [3] and the leading cause for which children seek medical advice, in both developed and developing countries [1, 4, 5] . Children less than 3 years of age have a high prevalence of OM, with the peak incidence occurring around 1 year of age [1, 5, 6] . Children under 2 years of age with six or more episodes of acute otitis media (AOM) are termed "otitis-prone" [1] . Though the prevalence of OM varies considerably between different population groups, the indigenous Australians, Inuits and American Indians have a high prevalence of OM [1, [7] [8] [9] and are considered to be high-risk populations.
The burden of OM in indigenous Australians
Epidemiological studies demonstrate a significant burden of chronic OM in different indigenous populations [8, 10] . Australian indigenous children are particularly susceptible to OM and have a prevalence that is amongst the highest in the world. In a systematic review of the burden of OM which included over 250,000 children from 108 studies, Gunasekera et al. concluded that the highest prevalence of the disease and its associated complications is seen in Australian indigenous children, citing that 84 % of these children had OM and 23 % also suffered hearing impairment [9] . Morris et al. assessed the middle ear status of children in 29 remote Aboriginal communities and found that 50 % of children between 6 and 30 months of age had suppurative ear disease and 25 % had perforated tympanic membranes [11] . According to the World Health Organization (WHO), a prevalence of more than 4 % of chronic OM in a defined population of children indicates a massive public health problem requiring urgent attention [12] .
Pathogenesis and clinical course of OM
The interaction between bacteria, viruses and the host immune response plays a role in the pathogenesis of AOM [1, 13] . AOM is usually initiated by respiratory viruses, and can be complicated by bacterial infection, which worsens the clinical outcome [14] . Streptococcus pneumoniae (the pneumococcus), Haemophilus influenzae and Moraxella catarrhalis are the main causative bacteria for AOM [1, 2, [15] [16] [17] [18] [19] [20] [21] . These pathogenic bacteria colonise the nasopharynx prior to the development of OM [15, [21] [22] [23] . As such, children may be asymptomatic carriers of such pathogens, or may develop infections such as suppurative OM [15, 22, 23] . There are several factors that contribute to the complex process of disease development. Under normal conditions, the low density of bacterial colonisation in the nasopharynx may initiate a host response that regulates the inflammatory process and eradicates these bacteria without causing mucosal damage [12, 21, 24] . In contrast, high bacterial loads in the nasopharynx compounded by early exposure to OM pathogens can cause repeated inflammation, mucosal damage and persistence of infection [21, 24] (Fig. 1) .
Increased pathogen loads in the nasopharynx are linked to an increased risk of upper respiratory tract infections, including OM [15, 25] . Smith-Vaughan et al. quantified the nasal bacterial load of the three main OM pathogens in otitis-prone Aboriginal children and non-Aboriginal children (the latter being at low risk for developing OM). High nasopharyngeal bacterial loads were significantly associated with severe OM, and were considered to be a sensitive measure of suppurative OM [15] . In a separate study, the early onset of OM (defined as occurring at 3 to 6 weeks of age) was significantly associated with increased bacterial loads of OM pathogens in comparison to other microbes in the nasopharyngeal microbiota in Aboriginal children [25] . Early (less than 3 months of age) colonisation of the nasopharynx with OM pathogens resulted in an increased risk of OM in a cohort of 306 US infants followed up from birth to 1 year of age [16] .
The microbial community of the upper respiratory tract develops soon after birth and is influenced by the environment and contact with other persons [26] . There is a dynamic interaction of competition and regulation between potentially pathogenic bacteria and commensals in the nasopharynx. Host immune responses can further affect the persistence or clearance of some species of bacteria [27] . The nasopharyngeal microbiota of children varies considerably between individuals and seasons [28] . In children with AOM, exposure to antimicrobials and prior pneumococcal vaccination (PCV7; heptavalent conjugate pneumococcal vaccine) were associated with a decrease in the prevalence of certain commensals (Streptococcaceae and Corynebacteriaceae) in the nasopharyngeal microbiota [29] . A case study which explored the microbiota of the middle ear, adenoids and tonsils in a child with chronic suppurative otitis media (CSOM) suggested that the adenoids may be a source for the microbiota in the middle ear and tonsils [30] .
In approximately 75 % of children with AOM, inflammatory symptoms including otalgia and fever resolve spontaneously within 2 days [21] , although asymptomatic effusion may be observed in a quarter of children even after 3 months [21, 31, 32] . In contrast, children in high-risk populations are more prone to early onset, recurrent episodes of AOM and are more likely to develop CSOM [31, 32] . CSOM causes recurrent ear discharge, perforation of the tympanic membrane and associated hearing impairment with poor speech and language development [5, 7, 33] , resulting in long-term impacts on cognitive and educational outcomes [33] .
Analysis of the nasopharyngeal swab and/or the middle ear fluid have demonstrated that the presence of certain respiratory viruses along with pneumococcus, H. influenzae and M. catarrhalis increased the risk of AOM in children [34, 35] . In addition, a high nasopharyngeal titre of respiratory syncytial virus (RSV) is associated with increased risk of AOM in children [13] . Viral infection of the upper airways is likely to play a role in the transmission of pneumococcal disease [19, [36] [37] [38] [39] , as evidenced by epidemiological studies that demonstrate an association between concomitant viral upper respiratory infection and horizontal spread of pneumococci amongst family members [40] . Furthermore, pneumococcal colonisation in humans [41] and mice [19, [42] [43] [44] is increased by infection with influenza A virus (IAV). In an infant mouse model that investigated pneumococcal-influenza synergism, young mice were colonised with pneumococci and, subsequently, with IAV 3 days later. IAV inoculation increased pneumococcal colonisation densities, induced the development of pneumococcal disease and was essential for pneumococcal transmission to contact mice [19, 43, 44] . This model was designed to mimic clinical aspects of pneumococcal nasopharyngeal colonisation, as it commonly occurs in young children with an immature immune system. Mice coinfected with pneumococci and IAV had high pneumococcal load in the middle ear with signs of middle ear inflammation when compared to mice infected with pneumococci alone [43] .
The host immune system plays a complex role in determining the progression of infection [3, 21] and also the prevention of OM [45] [46] [47] . An immature immune system may fail to elicit an adequate antibody response [48] to OM pathogens, leading to recurrence and chronicity of the disease [31] . A deficiency of secretory IgA, which reflects on the bacterial and viral adherence to the nasopharynx, is associated with recurrent AOM [31] . Delayed development of the immune system and abnormalities of the complement system have also been associated with the development of OM [2, 49] .
A number of other risk factors have been identified for OM among children. Lack of breast feeding, parental smoking, poor household sanitation [9] , younger children aged 6-17 months attending day care [50] , overcrowding and exposure to charcoal smoke [51] have all been shown to contribute to an increased risk for developing OM. Lower socioeconomic status with poor access to a health system has also been associated with a high prevalence of OM [31] .
Indigenous children usually develop OM early in life [21] , they experience frequent and severe episodes, and are more likely to develop complications compared to nonindigenous children [11, 31, [52] [53] [54] [55] [56] . Indigenous children may be more vulnerable to social disadvantage that may accompany long-standing hearing impairment [7, 57] . This dichotomy between indigenous and non-indigenous children in terms of incidence, pathogenesis, severity, complications and long-term outcomes of OM needs to be addressed in order to arrive at an effective management strategy for OM in high-risk populations [31] .
Streptococcus pneumoniae prevention and treatment strategies S. pneumoniae, a member of the commensal flora of the upper respiratory tract, colonises the nasopharynx [22] in early childhood, with the colonisation rates declining to less than 10 % in adult populations [23] . Children, the elderly and immunocompromised individuals are more susceptible to pneumococcal disease, which can range from localised infections such as OM and pneumonia to invasive disease such as septicaemia or meningitis [20, 22] .
Various preventive strategies and treatment options have significantly reduced the burden of pneumococcal infections. The introduction of PCV7 led to a significant reduction of invasive disease and pneumonia caused by vaccine serotypes of pneumococcus [20, 22] , mainly in developed countries, such as the USA [58] . However, the efficacy of PCV7 against OM has been limited [22] . Clinical trials of an 11-valent pneumococcal conjugate vaccine using an H. influenzae-derived protein D carrier showed reduced carriage of H. influenzae and vaccine serotypes of pneumococcus, and some benefit against OM [59, 60] . However, the 10-valent licensed version of this vaccine (PHiD-CV; PCV10) did not have a substantial effect on H. influenzae carriage [61] . Vaccination has also been associated with increased colonisation by pneumococcal serotypes not covered by the vaccine (serotype replacement) [62] [63] [64] , which also have the potential to cause OM [65] . A major limitation to vaccination is that the first dose is typically not administered until 2 months of age, by which point infants in highrisk populations may already be colonised by pneumococci [66] . Early life pneumococcal colonisation [25] , the low vaccination coverage among indigenous populations [67] and the high cost involved in vaccine production and delivery [66] are factors which call for more effective strategies to reduce the burden of OM in high-risk populations. Pneumococci are innately susceptible to the penicillin group of antibiotics, but the overuse of antibiotics has contributed to the development of resistant strains [22] . Treatment with antibiotics can disrupt the balance of the nasopharyngeal microflora, further facilitating colonisation with pathogens [68] . Both the long-term use of oral antibiotics [69] and pneumococcal vaccination [70] have been shown to decrease the prevalence of tympanic membrane perforation in young indigenous children but did not affect the prevalence of OM significantly [57] . Maternal pneumococcal vaccination trials are currently underway as possible strategies against middle ear infection and pneumococcal carriage among high-risk populations [71] . Nasopharyngeal colonisation is considered to be a prerequisite for pneumococcal infection [16, 72] . Adherence of the bacteria to the epithelial cells of the respiratory tract initiates the colonisation process [22, 23] . Since children can carry large numbers of pneumococci in the nasopharynx, they play a major role in the horizontal dissemination of the bacteria in the community, particularly in overcrowded situations [73, 74] . Hence, research focusing on methods to prevent the nasopharyngeal colonisation of pneumococci, especially during early stages of infancy [25] , has been considered as a promising strategy for controlling OM and improving herd immunity [22] . Many researchers have highlighted the need to decrease the bacterial load in the nasopharynx to bring about any significant change in the prevalence of OM in the Australian indigenous population [12, 15, 31, 75] .
Probiotics and OM
Probiotics as defined by the WHO are "live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host" [76] . Probiotics play a role in preventing diseases and re-establishing the microbial equilibrium of the intestinal tract [77] .
The mechanisms of probiotic action have been investigated using in vitro and in vivo models, as well as human studies. Some of the mechanisms by which probiotics are thought to act include the inhibition of pathogen colonisation by competition for nutrients and adhesion sites on the epithelium [78] , production of bacteriocins (antimicrobial compounds that can kill or inhibit other closely related bacterial species) [79, 80] and immune modulation by enhancing mucosal and systemic immunity [78, 81] . Immunomodulatory effects of probiotics include increased IgA production [82, 83] and modification of cytokine levels [84, 85] , as well as being effective vaccine adjuvants [66] . However, it is important to note that the effects of probiotics are dependent on the species and strain used [86] .
The administration of probiotics has demonstrated some beneficial results on upper respiratory infections, including OM [87, 88] (Table 1) . A study in which healthy adults drank a mixture containing four probiotic species, namely, Lactobacillus rhamnosus GG (LGG), Bifidobacterium sp., Lactobacillus acidophilus and Streptococcus thermophilus, found that this treatment significantly reduced the occurrence of nasal colonisation with potentially pathogenic bacteria such as Staphylococcus aureus, pneumococcus and beta-hemolytic streptococci [89] . The investigators suggested that the ingested probiotics stimulated the gutassociated immune system, which enhanced the mucosal immunity of the upper respiratory tract. Hatakka et al. [90] assessed the effect of LGG on respiratory infections, including OM, by feeding 571 healthy children milk with or without LGG for 7 months. Respiratory infections including OM and antibiotic treatment for respiratory infections were reduced in the probiotic group, but the differences in infection rates were not significant when adjusted for age. In a study in which 248 healthy children were given milk with or without Lactobacillus rhamnosus LB21 for 21 months, the number of days during which the children experienced OM was significantly lower in the treatment group [91] . However, when 309 OM-prone children were given either a probiotic capsule (containing LGG, L. rhamnosus LC 705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS) or placebo daily for 24 weeks, the two groups did not show statistically significant variations in the occurrence or recurrence of OM or the nasopharyngeal carriage of pneumococcus and H. influenzae, although a trend towards reduced recurrence of upper respiratory infections in the probiotic group was observed [92] .
Rautava et al. [93] assessed the effects of probiotics in reducing the risk of acute respiratory infection, including OM, in infancy. Infants less than 2 months of age requiring formula feeds were administered formula supplemented with the probiotics LGG and Bifidobacterium subsp. lactis Bb-12 (Bb 12) or with placebo daily, until the age of 1 year. The probiotic group experienced significantly fewer episodes of AOM and recurrent respiratory infections in the first 12 months of life. However, in another infant study, the consumption of Bb-12 was not associated with lower incidence of OM, although infants receiving Bb-12 did experience significantly fewer respiratory infections [94] . The mechanisms by which the oral ingestion of probiotics may exert effects in the upper respiratory tract remain unclear.
Alpha-haemolytic streptococci (AHS) as pharyngeal probiotics AHS are commensal inhabitants of the healthy nasopharynx that produce bacteriocins and have been investigated in clinical trials for their ability to inhibit OM pathogens through various mechanisms, including bacterial interference [95] [96] [97] [98] . Although some strains of AHS may cause infection [99] , most strains are well tolerated [97, [100] [101] [102] and have been safely used as probiotic supplements in a number of clinical studies and are commercially available. Roos et al. [95] investigated the effect of AHS administered as a nasal spray on the incidence of OM in 108 otitis-prone children aged 6 months to 6 years. Their results showed that the spray was effective in reducing the incidence of both recurrent AOM and secretory OM [95] . Based on these findings, a nasal spray containing AHS was investigated for efficacy in children under 4 years of age with OM, but there was no significant change in the nasopharyngeal microbiota or the number of OM episodes compared to the control group [97] . Nonetheless, there was a trend towards reduced carriage of H. influenzae and a lower number of OM episodes in the AHS-treated group towards the end of the study. The authors speculated that a higher dose of AHS with superior adherence properties may have yielded a better result. Furthermore, treatment with a course of antibiotics prior to the administration of the spray could have helped to reduce the pre-existing bacterial microbiota and promoted better adherence of the AHS to the nasopharyngeal mucosa. Both of these clinical studies used sprays consisting of five strains of AHS with in vitro activity against pneumococcus, H. influenzae and M. catarrhalis. Another study compared a nasal spray containing the probiotics S. sanguinis or L. rhamnosus with placebo in the treatment of established secretory OM in children with a median age of 6 months and reported that a 10-day administration of S. sanguinis-containing nasal spray was associated with a reduction in the presence of middle ear effusion [101] . After studying the bacteriology of the adenoids, Bernstein et al. [96] concluded that AHS are the predominant microbiota within the adenoids in non-OMprone children compared to OM-prone children [96] , and further investigation in vitro suggested that Streptococcus oralis, a member of the AHS, inhibits the OM otitis media; AOM acute otitis media; NS not significant; RR risk ratio; AHS alpha-haemolytic streptococci; CFU colony-forming units growth of pneumococcus [103] . This finding indicates that a nasal spray with AHS has the potential to recolonise the nasopharynx with safer streptococci and inhibit pathogenic bacteria. Streptococcus salivarius, an AHS isolated from the pharynx of a healthy person, is a potential pharyngeal probiotic, owing to its immunomodulatory and anti-inflammatory properties, good host adaptability and ability to produce plasmid-encoded broad-spectrum bacteriocins [80, 104, 105] . S. salivarius is well tolerated and considered to be safe for consumption by adults and children [106, 107] . The administration of S. salivarius tablets was associated with a reduction in Streptococcus pyogenes throat infections in a study of 40 adults with a history of recurrent streptococcal pharyngitis or tonsillitis [108] . In a similar study among 82 children, the administration of S. salivarius tablets for 90 days reduced AOM episodes and streptococcal throat infections during the 6-month follow-up period. This study also showed a reduction in OM during the treatment period compared to the previous year, but these findings need to be interpreted with caution, given the difference in time frames of the observation periods on and off treatment (3 vs. 12 months, respectively) [102] . In a pilot study of the oral administration of S. salivarius in OM-prone children, only a third became newly colonised with S. salivarius, indicating that dosing strategies need further optimisation [109] . Further studies using S. salivarius as a probiotic in otitis-prone children are worth considering, in addition to studies using lactic acid bacteria, which have also demonstrated the potential to prevent respiratory infections [110] and inhibit pneumococcal infections in mouse models [111, 112] . More data are also needed in order to determine which probiotic species and strains would be most effective in preventing colonisation by OM pathogens, and what would be the optimal dosing and administration strategies to evaluate clinical efficacy.
The evidence so far from various studies on the effect of probiotics on OM offers promising results and justifies further research in this field. Well-designed clinical trials can provide valuable information on widely used oral probiotics and more targeted AHS nasal spray in preventing OM, especially in high-risk populations.
Conclusions
Otitis media (OM) and its complications cause a significant burden on the health and well-being of high-risk populations. Research focused on determining the optimal use of preventive and intervention strategies, along with public health measures and evidence-based treatment options early in life, are warranted to reduce the prevalence of OM [12] .
Probiotics offer promising benefits in reducing nasopharyngeal colonisation with pathogenic bacteria and enhancing mucosal immunity, thus, potentially decreasing OM and upper respiratory infections. Due to the varied and limited data currently available, in vitro experiments together with animal studies could provide important information on the mechanisms of action and potential effectiveness of probiotics in this setting. Furthermore, well-designed clinical trials are needed in order to assess the effect of probiotics on pneumococcal infection and evaluate their potential as a novel strategy to reduce OM, especially in high-risk populations.
